May 3, 2022 Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
Apr 28, 2022 ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
Apr 7, 2022 ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
Mar 24, 2022 ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
Mar 22, 2022 ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders